Latest Healthcare News

Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.

Aroa Biosurgery has reported a strong first half for FY26, with 14% revenue growth driven by its Myriad product line and a return to positive EBITDA. The company also secured relief from ASX quarterly reporting requirements, signaling improved financial stability.

Aroa Biosurgery reported a 14% rise in product sales to NZ$44.6 million for the half-year ended September 2025, driven by strong growth in its Myriad portfolio. The company also posted a normalised EBITDA profit and reaffirmed its FY26 revenue and profit guidance.

Osteopore Limited has partnered with DKSH Malaysia in a five-year agreement to distribute its innovative dental products, aiming to capture significant growth in Malaysia’s guided bone regeneration sector.

Pacific Edge reports a $19.1 million net loss for the first half of FY26 amid Medicare coverage loss but positions itself for a Medicare-led recovery with strong clinical evidence and a key advisory committee meeting set for February 2026.

Race Oncology Limited has secured shareholder approval for a replacement Constitution at its 2025 Annual General Meeting, updating its corporate governance framework to align with current regulatory standards.

Pro Medicus Ltd has delivered a record-breaking FY2025 with revenue soaring nearly 32% and net profit up 39%, driven by landmark contracts and a robust growth pipeline.

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.

Monash IVF has decisively turned down a non-binding acquisition offer valuing its shares at $0.80, citing significant undervaluation and uncertain financing. The Board signals openness only to proposals that deliver compelling shareholder value.

Island Pharmaceuticals has secured membership in the Medical Countermeasures Coalition, positioning its antiviral Galidesivir for critical US government stockpiling and regulatory milestones.

New data reveals that Thoroughbred racehorses free from oxidative stress are significantly more likely to win or place, spotlighting OxiDx’s patented biomarker test as a game-changer in equine performance and welfare.

Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, has landed three new cloud-based contracts worth a combined minimum of A$29 million, reinforcing its strong foothold across diverse healthcare segments.